Author details

Full Name

James E Bradner

Affiliation

ORCID

Career Start Year

1995

Papers

262

H Index

106

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37237081	Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.	Nat Cancer	2023
37582753	Diversity-oriented synthesis encoded by deoxyoligonucleotides.	Nat Commun	2023
37989745	Author Correction: Diversity-oriented synthesis encoded by deoxyoligonucleotides.	Nat Commun	2023
36863346	Discovery and characterization of a selective IKZF2 glue degrader for cancer immunotherapy.	Cell Chem Biol	2023
35226736	BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes.	Blood	2022
35994477	A toolbox for class I HDACs reveals isoform specific roles in gene regulation and protein acetylation.	PLoS Genet	2022
35031563	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.	Proc Natl Acad Sci U S A	2022
34650218	Selective targeting of MYC mRNA by stabilized antisense oligonucleotides.	Oncogene	2021
34107377	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.	Neoplasia	2021
33547076	Targeting oncoproteins with a positive selection assay for protein degraders.	Sci Adv	2021
33406420	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins.	Cell Rep	2021
34396987	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia.	J Clin Invest	2021
34434504	Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.	Oncotarget	2021
32948771	Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules.	Nat Commun	2020
32483291	Selective Mediator dependence of cell-type-specifying transcription.	Nat Genet	2020
33016930	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma.	J Clin Invest	2020
32620694	Correction: Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of aurora kinases.	J Biol Chem	2020
30664779	Small-molecule targeting of brachyury transcription factor addiction in chordoma.	Nat Med	2019
31620231	Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold.	ACS Med Chem Lett	2019
30279226	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.	Blood	2019
30630822	Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.	Cancer Res	2019
31133746	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation.	Nat Genet	2019
31126889	The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.	EBioMedicine	2019
31431624	PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma.	Nature Communications	2019
31260717	Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465).	Exp Hematol	2019
31160565	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.	Nat Commun	2019
29581585	The dTAG system for immediate and target-specific protein degradation.	Nat Chem Biol	2018
29892083	Plasticity in binding confers selectivity in ligand-induced protein degradation.	Nat Chem Biol	2018
30503705	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.	Cancer Cell	2018
30397315	A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation.	Nat Cell Biol	2018
30590042	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.	Cell Rep	2018
30431433	Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.	Elife	2018
30102854	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains.	ACS Chem Biol	2018
29866822	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.	Proc Natl Acad Sci U S A	2018
29907650	JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.	Genes Dev	2018
30087114	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i>-Mutant Non-Small Cell Lung Cancer.	Cancer Immunol Res	2018
30125504	Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors.	J Med Chem	2018
29764999	Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.	Proc Natl Acad Sci U S A	2018
29356495	Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders.	ACS Chemical Biology	2018
29142067	JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma.	Mol Cancer Ther	2018
29444854	BET bromodomain proteins regulate enhancer function during adipogenesis.	Proceedings of the National Academy of Sciences of the United States of America	2018
29760044	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.	Cancer Res	2018
29180399	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma.	Blood	2018
29302039	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors.	Nat Commun	2018
29258295	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.	Nature	2018
29129717	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader.	Cell Chem Biol	2018
29379199	Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.	Nature Genetics	2018
29511348	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.	Oncogene	2018
29251720	Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation.	Nat Chem Biol	2018
29249691	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms.	Cancer Cell	2018